Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apellis Pharmaceuticals, Inc. filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company with common stock registered under the Exchange Act. The company’s 8-K reports cover product revenue disclosures for SYFOVRE and EMPAVELI, cash and financial-condition updates, and material agreements related to collaborations, royalty arrangements, financing consents, and strategic transaction activity.
Apellis filings also record governance and compensation matters, including board appointments, director compensation, executive separation and retention plans, and related equity-award provisions. These documents disclose formal corporate actions, capital-structure references, material-event reporting, and the company’s public-company obligations as a Delaware issuer.
A Form 144 notice was filed covering a planned sale of 10,186 shares of common stock, with an aggregate market value of $225,998.82. The shares are to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/13/2026. The securities relate to an issuer with 126,525,218 shares outstanding. The seller acquired these shares on 01/12/2026 through restricted stock vesting from the issuer as compensation.
APLS insider Timothy E. Sullivan has filed a notice of proposed sale of restricted stock under Rule 144. The planned transaction covers 3,856 shares of common stock to be sold through Fidelity Brokerage Services LLC on or about 01/13/2026 on the NASDAQ, with an aggregate market value of 85,553.84 based on the figures disclosed.
The shares to be sold were acquired from the issuer on 01/12/2026 through restricted stock vesting as compensation, with full amount of 3,856 shares acquired and paid on that date. Over the prior three months, Sullivan sold 10,000 common shares on 10/21/2025 for gross proceeds of 280,300.00.
By signing the notice, the seller represents that he does not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed and acknowledges that intentional misstatements or omissions can constitute federal criminal violations.
Apellis Pharmaceuticals, Inc. furnished an update on its recent performance by issuing a press release with preliminary unaudited U.S. net product revenues for the fourth quarter and full year ended December 31, 2025. The update covers revenues for its products SYFOVRE and EMPAVELI, along with the company’s cash and cash equivalents as of December 31, 2025. These figures are management’s estimates, remain subject to completion of normal year-end closing procedures, and have not been audited or reviewed by the company’s independent registered public accounting firm. The press release containing the detailed numbers is included as an exhibit to this report.
Apellis Pharmaceuticals general counsel David O. Watson reported an insider equity transaction. On January 7, 2026, he exercised a stock option for 888 shares of Apellis common stock at an exercise price of $14.95 per share. Following this option exercise, he directly holds 104,618 shares of Apellis common stock.
The filing also lists indirect holdings. A custodial account for his minor children holds 10,000 shares. In addition, 50,136 shares are held by The David O. Watson Irrevocable Trust of 2023, for which William Zorn serves as trustee; Watson disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest.
Apellis Pharmaceuticals Chief Medical Officer Caroline Baumal reported a sale of common stock. On January 5, 2026, she sold 3,020 shares of Apellis Pharmaceuticals, Inc. common stock at a price of $25.5287 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from Restricted Stock Units that were released on January 3, 2026, rather than as a discretionary open-market sale. Following this transaction, Baumal beneficially owns 91,206 shares of common stock directly, which includes 925 shares acquired through an employee stock purchase plan on October 31, 2025.
Apellis Pharmaceuticals officer David Watson reported a planned sale of 5,000 shares of Apellis common stock at $24.49 per share on December 16, 2025, coded as an "S" transaction. The filing notes this was a scheduled sale under a Rule 10b5-1 trading plan dated March 3, 2025.
After the sale, Watson directly owned 103,730 shares. He also had indirect ownership of 10,000 shares held in a custodial account for the sole benefit of his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Apellis Pharmaceuticals, Inc. (APLS) reported an insider transaction by its General Counsel, David Watson. On 11/17/2025, he sold 5,000 shares of common stock at a price of $20.06 per share in a transaction coded as a sale. The filing states this was a scheduled sale under a Rule 10b5-1 trading plan dated March 3, 2025.
After this transaction, David Watson beneficially owns 108,730 shares of Apellis common stock directly. He also reports indirect ownership of 10,000 shares through a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, over which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Apellis Pharmaceuticals (APLS) reported a profitable Q3 2025 driven by a major collaboration payment. Total revenue was $458.6 million versus $196.8 million a year ago. Product revenue was $177.8 million (SYFOVRE $150.9 million; EMPAVELI $26.8 million). Licensing and other revenue rose to $280.8 million, reflecting a $275.0 million upfront from Sobi under a royalty buy‑down effective July 1, 2025.
The company posted net income of $215.7 million (diluted EPS $1.67), compared to a net loss last year. Cash and cash equivalents were $479.2 million, with accounts receivable at $345.5 million. On the balance sheet, a senior secured credit facility had a $375.0 million principal balance, and $93.9 million of convertible notes remained outstanding, reclassified as current as they mature on September 15, 2026. The FDA approved EMPAVELI for C3G and IC‑MPGN on July 28, 2025, expanding its rare disease indications. As of October 23, 2025, shares outstanding were 126,525,218.
Apellis Pharmaceuticals (APLS) reported an insider transaction by CFO Timothy Sullivan. On October 21, 2025, he exercised stock options for 10,000 shares at $10.03 and sold 10,000 shares at $28.03 under a Rule 10b5-1 trading plan.
After these transactions, he held 110,936 shares directly and 60,396 shares indirectly through The Timothy E Sullivan Irrevocable Trust of 2023. He also reported 232,903 derivative securities (stock options) beneficially owned following the transactions.
Apellis Pharmaceuticals (APLS) General Counsel David Watson reported a sale of 5,000 shares of common stock at $25.22 on 10/16/2025 pursuant to a Rule 10b5-1 trading plan dated March 3, 2025.
After the transaction, he beneficially owned 113,730 shares directly, plus 10,000 shares held indirectly via a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023.